Comment by sonicggg
3 years ago
After reading it, my suspicion was confirmed. Yet another mab. Very powerful, but expensive to scale and synthesise. I guess poor people will have to just suck it up and die. We don't have the tech yet to make these cost effective. Big pharma loves this natural barrier of entry though.
Also, don't expect this stuff to be available anytime soon. FDA process is pretty slow, and sometimes political. Maybe if it were effective against Sars-Cov-2, FDA would be willing again to rush it though the door. Still can't wrap my head around how stuff like Molnupiravir made the cut. They just don't have any shame.
-mab drugs really are incredible. I actually take 2 different ones (erenumab and omalizumab), and the results surpassed all my expectations, especially after negative or lacklustre results from many "conventional" medications beforehand.
But aye, they aren't cheap.
There were times when aluminium was so expensive that the French emperor dined on an aluminium plate. His guests had to do with gold and silver. Several decades later, aluminium was an everyday material.
I definitely hope that we can come with a cheap method of -mab production. I am almost sure we one day will.
This is why there is a fast-track to accelerate break-through treatments, which dostarlimab utilized (but stalled thanks to covid):
https://www.fda.gov/patients/learn-about-drug-and-device-app...
But, yeah, the FDA is all over the place.